lichen planopilaris. Chapter XII Diseases of the skin and subcutaneous tissue(L00-L99)
Conditions
Interventions
Intervention 1: Intervention group: tablet baricitinib 4 miligram daily oral intake. Intervention 2: Control group: clobetasol topical lotion 0.05% once daily ,topical.
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 70 Years
Inclusion criteria
Inclusion criteria: Age between 15 and 70 years Acceptance of all provisions of informed consent regarding the plan Absence of contraindications for baricitinib use, including chronic renal failure with GFR below 30, severe liver failure, sensitivity to baricitinib, severe anemia with hemoglobin below 8, lymphopenia with an absolute lymphocyte count below 500, or neutropenia with an absolute neutrophil count below 1000, pregnancy and breastfeeding Not being pregnant and not taking OCP Severe and expanding multifocal disease that is a candidate for receiving systemic medication according to the opinion of the main executive of the plan. Not taking drugs that interact with baricitinib The patient's consent to enter the plan
Exclusion criteria
Exclusion criteria: For any reason, the patient does not agree to enter the plan For any reason, the patient does not agree with the provisions of informed consent in the plan Contraindications to baricitinib use include chronic renal failure with GFR below 30, severe liver failure, sensitivity to baricitinib, severe anemia with hemoglobin below 8, lymphopenia with an absolute lymphocyte count below 500, or neutropenia with an absolute neutrophil count below 1000, pregnancy and breastfeeding Pregnancy or OCP consumption Local and limited disease that is not a candidate for receiving systemic and immunosuppressive drugs according to the opinion of the main executive of the plan. Taking drugs that interfere with baricitinib
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage reduction of LICHEN PLANOPILARIS ACTIVITY INDEX score. Timepoint: At the beginning of the study (before the start of the intervention) and 2, 4 and 6 months after the start of the study. Method of measurement: Lichen planopilaris disease activity index questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Aspartate aminotransferase. Timepoint: The beginning of the study (before the start of the intervention) and 2, 4, and 6 months after the start of the study. Method of measurement: blood test.;Alanine aminotransferase. Timepoint: The beginning of the study (before the start of the intervention) and 2, 4, and 6 months after the start of the study. Method of measurement: blood test.;Alkaline phosphatase. Timepoint: The beginning of the study (before the start of the intervention) and 2, 4, and 6 months after the start of the study. Method of measurement: blood test.;Creatinine. Timepoint: The beginning of the study (before the start of the intervention) and 2, 4, and 6 months after the start of the study. Method of measurement: blood test.;Blood urea nitrogen. Timepoint: The beginning of the study (before the start of the intervention) and 2, 4, and 6 months after the start of the study. Method of measurement: blood test.;Complete blood count. Timepoint: The beginning of the study (before the start of the intervention) and 2, 4, and 6 months after the start of the study. Method of measurement: blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFateme Ghaseminia
Tehran University of Medical Sciences
Outcome results
None listed